Incorporation of decay-accelerating factor into the baculovirus envelope generates complement-resistant gene transfer vectors

Nature Biotechnology

Volumn 19, Issue 5, 2001, Pages 451-455

  Hüser, Andreas ^a   Rudolph, Michael ^b   Hofmann, Christian ^a  

^a DeveloGen AG   (Germany)

^b LEIBNIZ INSTITUTE FOR ZOO AND WILDLIFE RESEARCH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ELECTRON MICROSCOPY; PROTEINS; VIRUSES;

IMMUNOBLOTTING;

GENE TRANSFER;

COMPLEMENT; DECAY ACCELERATING FACTOR; VIRUS VECTOR;

ANIMAL EXPERIMENT; ARTICLE; BACULOVIRUS; CONTROLLED STUDY; ELECTRON MICROSCOPY; EXPRESSION VECTOR; GENE TARGETING; GENE TRANSFER; IMMUNOBLOTTING; NONHUMAN; PRIORITY JOURNAL; RAT; VIRUS ENVELOPE; VIRUS INACTIVATION; VIRUS MUTANT; VIRUS MUTATION;

ANIMALS; ANTIGENS, CD55; BACULOVIRIDAE; COMPLEMENT ACTIVATION; COMPLEMENT INACTIVATOR PROTEINS; COMPLEMENT SYSTEM PROTEINS; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMANS; IMMUNOBLOTTING; MICROSCOPY, ELECTRON; RATS; RECOMBINANT FUSION PROTEINS; TUMOR CELLS, CULTURED; VIRAL FUSION PROTEINS;

ANIMALIA; DNA VIRUSES; UNIDENTIFIED BACULOVIRUS;

EID: 0035005986     PISSN: 10870156     EISSN: None     Source Type: Journal    
DOI: 10.1038/88122     Document Type: Article

References (41)

1. Gene therapy - Promises, problems and prospects
2. Efficient gene transfer into human hepatocytes by baculovirus vectors
3. Baculovirus-mediated gene transfer into mammalian cells
4. Efficient gene transfer into various mammalian cells, including nonhepatic cells, by baculovirus vectors
5. Transient and stable gene expression in mammalian cells transduced with a recombinant baculovirus vector
6. Efficient transduction of mammalian cells by a recombinant baculovirus having the vesicular stomatitis virus G glycoprotein
7. Site-specific integration in mammalian cells mediated by a new hybrid baculovirus-adeno-associated virus vector
8. Gene transfer into hepatocytes and human liver tissue by baculovirus vectors
9. Complement activation in rats by liposomes and liposome-encapsulated hemoglobin: Evidence for anti-lipid antibodies and alternative pathway activation
10. Liposome-induced activation of the classical complement pathway does not require immunoglobulin
11. Activation of the complement system by synthetic DNA complexes: A potential barrier for intravenous gene delivery
12. Human serum lyses RNA tumour viruses
13. Sensitization of cells and retroviruses to human serum by (α1-3) galactosyltransferase
14. Baculovirus-mediated gene transfer in the presence of human serum or blood facilitated by inhibition of the complement system
15. The baculovirus vector system for gene delivery into hepatocytes
16. Controlling the complement system in inflammation
17. Localization of classical and alternative pathway regulatory activity within decay-accelerating factor
18. Complement in human reproduction: Activation and control
19. Coating of human decay accelerating factor (hDAF) onto medical devices to improve biocompatibility
20. Complement activation, its consequences, and blockade by gene transfer
21. Host cell-derived complement control proteins CD55 and CD59 are incorporated into the virions of two unrelated enveloped viruses
22. Role of virion-associated glycosylphosphatidylinositol-linked proteins CD55 and CD59 in complement resistance of cell line-derived and primary isolates of HIV-1
23. Efficient destruction of human immunodeficiency virus in human serum by inhibiting the protective action of complement factor H and decay accelerating factor (DAF, CD55)
24. Neutralization of budded Autographa californica nuclear polyhedrosis virus by a monoclonal antibody: Identification of the target antigen
25. Eucaryotic virus display: Engineering of the major surface glycoprotein of the Autographa californica nuclear polyhedrosis virus (AcNPV) for the presentation of foreign proteins on the virus surface
26. Virus host interactions
27. Establishment of complement-resistant retroviral vector by homologous restriction factor 20 gene
28. Complement defense mechanisms
29. Decay-accelerating factor: Biochemistry, molecular biology, and function
30. Evasion of complement-mediated damage by microorganisms
31. Strategies for targeted gene therapy
32. Complement-dependent virus neutralization
33. Defense against bacteria
34. Human and rodent decay-accelerating factors (CD55) are not species-restricted in their complement-inhibiting activities
35. Efficient transduction of neural cells in vitro and in vivo by a baculovirus-derived vector
36. Cerebrospinal fluid C3 and C4 indexes in immunological disorders of the central nervous system
37. Growth of human hepatoma cell lines with differentiated functions in chemically defined medium
38. Liposome-encapsulated DNA-mediated gene transfer and synthesis of human factor IX in mice
39. Monoclonal antibodies to baculovirus structural proteins: Determination of specificities by western blot analysis